M. E. Garza's  Instablog

M. E. Garza
Send Message
M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he began... More
My company:
My blog:
Daily Info Feeds and Updates
  • Closer look at BioElectronics Corporation (OTC:BIEL) Continued 8 comments
    Jul 15, 2009 3:34 PM | about stocks: BIEL

    Yesterday I posted the first of a two part interview with Joseph Noel, a spokesman for BioElectronics Corporation (OTC:BIEL). We took an interest in BIEL because the company appears poised for continued strong revenue growth and as you can see in our exclusive BioMedReports FDA Calendar, they have not one, but two applications with the FDA for 510(k) marketing clearance. In addition, we learned that the company is getting ready to file at least two additional FDA applications.

    Here is the second part of that interview:

    The company recently announced a new Chairman.  What can you tell us about that development?

    Noel: Rick Anderson, who is a full professor at the Fuqua School, one of the top business school, as part of the Duke University.  He had been a board member, and he came on board to be Chairman of the Board.  He's got significant FDA consulting experience, a very experienced market researcher, so he's been instrumental in helping guide the management team toward these clinical studies  and the filing for indications.

    As you are looking at obviously expanding the market for these products, you've got several applications, like you said, with the FDA, you've got worldwide sales, etc..  Are there any developments, or anything you can talk about as far as the preparation for hitting the marketplace with this products, or partnerships, or anything like that?

    Noel: Well, we're a small company, so we have distributors around the world.  I shouldn't say around the world.  We have several distributors in various companies.  Canada has been the most successful thus far.  We have very big hopes for Italy and Northern Europe, where we have two very aggressive distributors. 

    In the US, however, all we do is, you know, we can't hire a sales force to go market to plastic surgeons for blepharoplasty, which is eyelid surgery, that makes no sense.   And of course, you can't market off-label, so we haven't done basically anything in the States.  In the States, however,  we have had conversations with manufacturers and distributors of feminine hygiene products, who have experienced significant interest in a delayed menstrual pain relief products, but they're all preliminary discussions.  They say, "Great, let us know what happens with the FDA, because we're all interested." 

    For general plastic surgery, we've got some other avenues to pursue, but, again, we believe that the big market for this is a treatment for musculoskeletal complaints - back pain, knee pain, things like that.  The market in Canada is actually pretty incredible.  The distributor has learned that the primary target market is elderly women with chronic pain, and we think that the market in the US for that is very significant.  We can develop that market ourselves, and put it on the store shelves.  I'm assuming we’d get over-the-counter clearance, which I think we will.  Probably a more likely avenue, is we'll pick a major distributor of drug store, on-the-shelf products to help us out.

    Great, let's see, is there anything else that you might want the investment community to be aware of, as far as Bioelectronics?

    Noel: We pretty much covered it.  It's a group of people who've developed what we think is a revolutionary technology.  We think the timing is perfect, considering that there's a very high likelihood that the FDA is going to make drugstores pull extra strength Tylenol off the market.  I think that’s going to speak volumes about the safety of that particular drug.  FDA is saying “Acetaminophen is not candy.”  Don't pop a couple in the morning, maybe you take a Nyquil at night, have a couple of cocktails, and then get up in the morning and take some more extra strength Tylenol because your back hurts.  That has a negative affect on your liver, it's just a fact, and we think that that will help a lot of people start saying, "Well, maybe I just don't want to take a pill.  What else can I use?" We think we've got a great alternative for that.

    One thing that I missed was pricing, how expensive are these devices?

    Noel: They retail for $39.95 in Canada.  They're not available over the counter in the United States, but we think it's a similar type of price, and the pricing in Europe is roughly equivalent.  We recently moved all of our manufacturing to China.  We gained a significant improvement in quality by doing that, and we significantly lowered our costs, so our gross margins on our costs of goods sold, versus retail level, is about seventy-five percent gross margin.

    Where were you producing before, here in the States?

    Noel: We actually produced in the States, and we had some problems with the epoxies that were used, the connections to the power unit, and frankly, that set the company back.  A lot of physicians and plastic surgeons wanted to use the product, but they're not going to mess around with something that's not one hundred percent reliable.  The difference is that the new products are bullet-proof.  You pull the pin out, it lasts for at least thirty days.  Women can use it for their menstrual cycle for three periods.  People in Canada are using them for forty-five days for back pain; extremely reliable product right now.


    It’s important to note that the process of treating soft tissue injury has advanced very little in the medical field.  The process that has been in place and pretty much standard operating procedure that has been in place for over a thousand years, really.  When someone gets a cut, a bad bruise or a sprain doctors typically clean the affected area, wrap it in some type of bandage in an attempt to prevent infection and then immobilize the injured part of the body.  Meanwhile, the patient endures the pain and waits while his body recovers and heals. What this company is attempting to do in order to address and change this process makes this investment quite interesting. Purely from a financial standpoint, the multiple applications for the product are multitudinous yet certainly as numerable as they are potentially profitable.

    As with many other biomedical companies, a lot is riding on the upcoming approvals and future marketing clearances of these devices by the FDA, but the odds for positive nods and continued market growth look very favorable. In addition, the media attention and customer reviews of the product (see video on left for one recent example) will likely continue to propel adoption of the technology by the general public.

    Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here.

    Disclosure: Long BIEL

    Stocks: BIEL
Back To M. E. Garza's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (8)
Track new comments
  • DuckThis
    , contributor
    Comments (14) | Send Message
    M.E. What's your thoughts on biel now 8-25-09
    25 Aug 2009, 06:11 PM Reply Like
  • M. E. Garza
    , contributor
    Comments (122) | Send Message
    Author’s reply » Still going up. Great product. Lots of approvals in their future and great marketing team. This is only the beginning of a great story.
    27 Aug 2009, 02:53 AM Reply Like
  • User 478800
    , contributor
    Comment (1) | Send Message
    Do you have a 6-12 month price target on biel? Looks like a few more filings this week and we should hear on one approval very soon...
    On Aug 27 02:53 AM M. E. Garza wrote:


    > Still going up. Great product. Lots of approvals in their future
    > and great marketing team. This is only the beginning of a great story.
    8 Sep 2009, 06:22 PM Reply Like
  • M. E. Garza
    , contributor
    Comments (122) | Send Message
    Author’s reply » I don't but one analyst has a short term price traget between $.30 and $.50 should the company get their peding FDA approval.
    11 Sep 2009, 07:16 AM Reply Like
  • DuckThis
    , contributor
    Comments (14) | Send Message
    The wind is in the sails for biel, alot of good things coming togather. The Perfect Storm. This is still an inexpensive stock compared to where it may/should go with it's stable.
    12 Sep 2009, 10:41 PM Reply Like
  • M. E. Garza
    , contributor
    Comments (122) | Send Message
    Author’s reply » Yeah, I agree. The only "problem" I see is that they have way too many shares out there. But then again.. It's all about how people are feeling and maybe they feel this is a multi-billion dollar product and the market cap will justify that?
    14 Sep 2009, 03:54 AM Reply Like
  • Anhngheo28(JJ)
    , contributor
    Comment (1) | Send Message
    Mr. Garza,
    what do you think about LLBO? thanks
    18 Sep 2009, 05:48 AM Reply Like
  • deeppocketsgolf
    , contributor
    Comments (111) | Send Message
    BioElectronics Corp. (BIEL); Last .0054 on 3.6M Shares;


    Market Cap 8M;


    Recent Monthly Volume: 132M; YTD Volume 375M;


    Last Report Filed: 3rd Qtr 2010; for Share Equity of (2.475M), with Accumulated Deficit of (12.599M); Paid In Equity: 10.1238M; Sales 4.115M; Since ’00; Development Stage Since April-2000;


    Subsequently Filed Form 15-12 with the Securities and Exchange Commission; Suspend Reporting Requirements; As of 4-19-11;


    PROForma Criteria:
    If the company were to commence reporting by reporting a Net Loss of 1.700M; What would it look like???


    Report Category, Report, Price, Metric,, Weight, Primary Weight Adj Trading Metric, Year / Desig, Weight Adj Price.


    20.15, Report a Net Loss of $1.700M , PROforma; 0.0045 , Primary, (4.17) , Weighted to Price Change; 4.2215404 , Combined; (17.2) , Avg Price 5.00 DAYS, 0.0045


    Weighted to Current Price / Price Range: ,for +$1.36M Market Cap, for, +0.0009, on adjusted level price of .0045;








    Mid 2006: 26 Cents;


    Per Last Year: (.027) to (.0012);


    (Minus): Level price of .011136 Oct-10 to Apr-11; Started to drop to current level;


    1 PKR = 0.0111036 AUD
    1 AUD = 90.0610 PKR


    Disclosure:[x]Own Shares and Follow the Company;
    15 May 2011, 03:30 AM Reply Like
Full index of posts »
Latest Followers


  • Hearing some interesting developments on the horizon for $NWBO. Did an article on them yesterday. Looks promising. http://bit.ly/NWBOnews
    Jul 12, 2011
  • ($RXPC.PK 3 of 3) If it were bad news, chances are they'd have something by now, since delisting decisions are usually handed down quickly.
    Apr 19, 2011
  • ($RXPC.PK 2 of 3) a listing extension would go until July [when the stock would have to be over $1 to continue being listed on Amex].
    Apr 19, 2011
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.